130 related articles for article (PubMed ID: 17763056)
1. Influence of polymers on the bioavailability of microencapsulated celecoxib.
Homar M; Ubrich N; El Ghazouani F; Kristl J; Kerc J; Maincent P
J Microencapsul; 2007 Nov; 24(7):621-33. PubMed ID: 17763056
[TBL] [Abstract][Full Text] [Related]
2. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
3. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
Ayalasomayajula SP; Kompella UB
Eur J Pharmacol; 2005 Mar; 511(2-3):191-8. PubMed ID: 15792788
[TBL] [Abstract][Full Text] [Related]
4. Formulation and development of floating capsules of celecoxib: in vitro and in vivo evaluation.
Ali J; Arora S; Ahuja A; Babbar AK; Sharma RK; Khar RK
AAPS PharmSciTech; 2007 Dec; 8(4):E119. PubMed ID: 18181540
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib.
Ali J; Tyagi P; Ahuja A; Baboota S; Hasan S
PDA J Pharm Sci Technol; 2007; 61(2):88-96. PubMed ID: 17479716
[TBL] [Abstract][Full Text] [Related]
6. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage.
Nagarsenker MS; Joshi MS
Drug Dev Ind Pharm; 2005 Jan; 31(2):169-78. PubMed ID: 15773284
[TBL] [Abstract][Full Text] [Related]
8. Three levels face centered central composite design of colon targeted micro-particulates system of celecoxib: screening of formulations variables and in vivo studies.
Nandy BC; Verma V; Dey S; Mazumder B
Curr Drug Deliv; 2014; 11(5):621-35. PubMed ID: 24844925
[TBL] [Abstract][Full Text] [Related]
9. Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.
Subramanian N; Ghosal SK; Moulik SP
Drug Dev Ind Pharm; 2005 May; 31(4-5):405-16. PubMed ID: 16093206
[TBL] [Abstract][Full Text] [Related]
10. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.
Nasr M
AAPS PharmSciTech; 2013 Jun; 14(2):719-26. PubMed ID: 23543607
[TBL] [Abstract][Full Text] [Related]
11. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
Amrite AC; Ayalasomayajula SP; Cheruvu NP; Kompella UB
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1149-60. PubMed ID: 16505053
[TBL] [Abstract][Full Text] [Related]
12. Evaluating tamsulosin hydrochloride-released microparticles prepared using single-step matrix coating.
Maeda A; Shinoda T; Ito N; Baba K; Oku N; Mizumoto T
Int J Pharm; 2011 Apr; 408(1-2):84-90. PubMed ID: 21291970
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization and in vitro studies of celecoxib-loaded poly(ortho ester) nanoparticles targeted for intraocular drug delivery.
Palamoor M; Jablonski MM
Colloids Surf B Biointerfaces; 2013 Dec; 112():474-82. PubMed ID: 24103464
[TBL] [Abstract][Full Text] [Related]
14. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
Jain SK; Gupta Y; Jain A; Bhola M
Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
[TBL] [Abstract][Full Text] [Related]
15. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
[TBL] [Abstract][Full Text] [Related]
16. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
[TBL] [Abstract][Full Text] [Related]
17. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration.
Ayalasomayajula SP; Kompella UB
Pharm Res; 2004 Oct; 21(10):1797-804. PubMed ID: 15553225
[TBL] [Abstract][Full Text] [Related]
18. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
19. Influence of polymer blends on the characterization of gliclazide--encapsulated into poly (ε-caprolactone) microparticles.
Barakat NS; Shazly GA; Almedany AH
Drug Dev Ind Pharm; 2013 Feb; 39(2):352-62. PubMed ID: 22540378
[TBL] [Abstract][Full Text] [Related]
20. Preparation and in vivo evaluation of spray dried matrix type controlled-release microparticles of tamsulosin hydrochloride for orally disintegrating tablet.
Park CW; Kim JY; Rhee YS; Oh TO; Ha JM; Park ES
Drug Dev Ind Pharm; 2012 Oct; 38(10):1179-87. PubMed ID: 22200122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
